# DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

> **NCT05496595** · PHASE1 · TERMINATED · sponsor: **DynamiCure Biotechnology** · enrollment: 5 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** DCBY02

## Key facts

- **NCT ID:** NCT05496595
- **Lead sponsor:** DynamiCure Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-26
- **Primary completion:** 2024-02-05
- **Final completion:** 2024-02-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Review of Data, and our other compound is a better option
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496595, "DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05496595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*